Aikido Pharma Inc AIKI:NASDAQ

Last Price$0.67NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.67 (5)
Ask (Size)$0.68 (263)
Day Low / HighN/A - N/A
Volume2.2 M

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Aikido Pharma Inc ( NASDAQ )

Price: $0.67
Change: -0.03 (3.87%)
Volume: 2.2 M
4:00PM ET 12/03/2021

Aware Inc ( NASDAQ )

Price: $2.89
Change: -0.03 (1.03%)
Volume: 40.2 K
4:00PM ET 12/03/2021

Inuvo Inc ( NYSE MKT LLC )

Price: $0.54
Change: -0.03 (4.66%)
Volume: 1.5 M
8:00PM ET 12/03/2021

Onemarket Ltd ( OTC )

Price: $0.54
Change: 0.00 (0.00%)
Volume: 90.00
8:30AM ET 5/09/2019

Streamline Health Solutions Inc ( NASDAQ )

Price: $1.38
Change: +0.03 (2.22%)
Volume: 105.4 K
4:00PM ET 12/03/2021

Read more news Recent News

--HC Wainwright Starts AIkido Pharma at Buy With $2 Price Target
6:47AM ET 10/11/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AIkido Pharma Acquires Equity Interest in Tevva Motors
11:04AM ET 9/28/2021 MT Newswires

AIkido Pharma (AIKI) said Tuesday it acquired an equity interest of an undisclosed size in UK-based electric truck manufacturer Tevva Motors. Tevva's core...

AIkido Acquires Stake in Tele-Health Company Kerna Health; Share Down
12:53PM ET 9/20/2021 MT Newswires

AIkido Pharma (AIKI) reported Monday that it has acquired an equity interest in tele-health company Kerna Health. Financial terms were not disclosed. Kerna...

AIkido Pharma, University of Maryland Identify Four Lead Compounds Blocking Viral Replication
11:13AM ET 7/16/2021 MT Newswires

AIkido Pharma (AIKI) and its partner, the University of Maryland, have identified four lead compounds that could inhibit the replication of multiple...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionAIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY. View company web site for more details
AddressOne Rockefeller Plaza
New York, New York 10020
Number of Employees6
Recent SEC Filing11/10/202110-Q
CEO, Chief Financial Officer & DirectorAnthony C. Hayes

Company Highlights

Price Open$0.69
Previous Close$0.70
52 Week Range$0.55 - 2.55
Market Capitalization$60.3 M
Shares Outstanding89.7 M
SectorHealth Technology
Next Earnings Announcement03/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.08
Beta vs. S&P 500N/A
Revenue$28.0 K
Net Profit MarginN/A
Return on Equity-5.92%

Analyst Ratings as of 10/08/2021

Consensus RecommendationConsensus Icon
Powered by Factset